News Releases

2002

XXX
Dec.12,2002
Ono Obtains an ISO14001 Certification for Its Fujiyama Plant (14.8KB)
XXX
Nov.01,2002
Discontinuation of ONO-6818 Development for Chronic Obstructive Pulmonary Disease and Alpha 1 Antitrypsin Deficiency (6.8KB)
XXX
Sep.18,2002
Announcement regarding the Results of Repurchese of Own Shares through ToSTNeT-2 (13.3KB)
XXX
Sep.17,2002
Notice regarding Repurchase of Own Shares through ToSTNeT-2 (17.1KB)
XXX
Sep.09,2002
Announcement of the Suspension of Overseas Clinical Study with Elaspol® 100 for Injection (66.2KB)
XXX
Sep.05,2002
Announcement of the Launch of Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker
XXX
Aug.26,2002
Schering-Plough launched Leukotriene Antagonist Pranlukast in Mexico
XXX
Jul.30,2002
Ono Pharmaceutical Received Approval to Relinquish the Entrusted Portion of the Employee Pension Fund
XXX
Jul.23,2002
Announcement of Manufacturing Approval for Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker
XXX
Jun.13,2002
Announcement of the Launch of Elaspol® 100 for Injection, the World's First Drug for Acute Lung Injury
XXX
May.17,2002
Notice regarding Repurchase of Ono Pharmaceutical's Own Shares(Under Article 210 of Japanese Commercial Code)
XXX
May.17,2002
Ono Pharmaceutical Improves Efficiency of Its Production System
XXX
May.15,2002
Announcement of Manufacturing Approval for Elaspol® 100 for Injection, the World's First Drug for Acute Lung Injury
XXX
Jan.28,2002
Notice regarding Purchase of Ono Pharmaceutical's Own Shares in the Market